Edition:
India

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

13.99USD
13 Sep 2019
Change (% chg)

$-0.14 (-0.99%)
Prev Close
$14.13
Open
$14.25
Day's High
$14.45
Day's Low
$13.63
Volume
170,020
Avg. Vol
192,786
52-wk High
$21.77
52-wk Low
$8.78

Latest Key Developments (Source: Significant Developments)

Flexion Therapeutics Posts Qtrly Loss Per Share Of $0.96
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS REPORTS SECOND-QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 SALES $17 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.7 MILLION.QTRLY LOSS PER SHARE $0.96.Q2 EARNINGS PER SHARE VIEW $-1.05 -- REFINITIV IBES DATA.  Full Article

Flexion Therapeutics Announces Preliminary, Unaudited Q4 2018 Results
Friday, 4 Jan 2019 

Jan 3 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH-QUARTER AND FULL-YEAR 2018 REVENUE AND INITIAL REVENUE GUIDANCE FOR 2019.SEES FY 2018 REVENUE $22.5 MILLION.SEES Q4 2018 REVENUE $9.5 MILLION.FULL-YEAR 2018 REVENUE ESTIMATED TO BE APPROXIMATELY $22.5 MILLION.FLEXION PROVIDING INITIAL 2019 PRODUCT REVENUE GUIDANCE OF $65 TO $80 MILLION.ANTICIPATES 2019 ZILRETTA PRODUCT REVENUE TO BE IN RANGE OF $65 TO $80 MILLION.Q4 REVENUE VIEW $10.2 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $23.1 MILLION -- REFINITIV IBES DATA.  Full Article

Flexion Therapeutics Reports Q3 Sales of $7.0 Million
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS REPORTS THIRD-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 SALES $7.0 MILLION VERSUS I/B/E/S VIEW $6.7 MILLION.QTRLY LOSS PER SHARE $1.15.Q3 EARNINGS PER SHARE VIEW $-1.20 -- THOMSON REUTERS I/B/E/S.  Full Article

Flexion Therapeutics Reports Q4 Sales $355,000
Friday, 9 Mar 2018 

March 8 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 SALES $355,000.Q4 REVENUE VIEW $600,000 -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $-1.11, REVENUE VIEW $599670.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Flexion Therapeutics Acquires Rights To Genequine Biotherapeutics' Non-Opioid Drug
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS ANNOUNCES ACQUISITION OF NOVEL, NON-OPIOID ASSET FOR OSTEOARTHRITIS OF THE KNEE.FLEXION THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT WITH GENEQUINE BIOTHERAPEUTICS GMBH TO ACQUIRE GLOBAL RIGHTS TO GQ-20.FLEXION THERAPEUTICS - CO OBTAINED EXCLUSIVE LICENSE TO UNDERLYING INTELLECTUAL PROPERTY RIGHTS FOR HUMAN USE OF GQ-203 FROM BAYLOR COLLEGE OF MEDICINE.FLEXION THERAPEUTICS - CO TO MAKE UPFRONT PAYMENT OF $2 MILLION TO GENEQUINE & MAY INCUR MILESTONE PAYMENTS OF UP TO $8.7 MILLION THROUGH PHASE 2 POC.  Full Article

Flexion therapeutics reports third-quarter results
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights.Flexion Therapeutics Inc - qtrly basic and diluted net loss per share $1.07‍​.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces pricing of public offering of common stock.Says public offering of 4.80 million common shares priced at $25.50per share.  Full Article

Flexion Therapeutics- Proposed public offering of 4 mln common shares
Wednesday, 11 Oct 2017 

Oct 10 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces proposed public offering of common stock.Says offering 4.00 million common shares.Flexion Therapeutics Inc - Flexion intends to use net proceeds from offering to fund manufacturing and commercialization of Zilretta(TM)​.  Full Article